NAARDEN, Netherlands, & MUNICH–(BUSINESS WIRE)–Forbion, a leading European life science venture capital firm, today announces that it has led a €17m Series C financing of OMEICOS Therapeutics GmbH, a privately held biopharmaceutical company based in Berlin, Germany. Forbion is the only new investor participating in the financing round, contributing €12.5m […]
Author: Ken Dropiewski
Stereotaxis to Report Third Quarter 2018 Financial Results on November 12, 2018
ST. LOUIS, Nov. 02, 2018 (GLOBE NEWSWIRE) — Stereotaxis, Inc. (OTCQX: STXS), the global leader in innovative robotic technologies for the treatment of cardiac arrhythmias, today announced that it will release financial results for its 2018 third quarter ended September 30, 2018 on Monday, November 12, 2018 before the open […]
Caladrius Biosciences to Host Third Quarter 2018 Financial Results Conference Call on Thursday, November 8, 2018 at 4:30 p.m. ET
BASKING RIDGE, N.J., Nov. 02, 2018 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company with multiple technology platforms targeting select cardiovascular indications and autoimmune diseases, announces that the Company will release financial results for the three and nine months ended September 30, 2018 […]
Digirad Corporation Reports Financial Results for the Third Quarter and Nine Months Ended September 30, 2018
SUWANEE, Ga., Nov. 02, 2018 (GLOBE NEWSWIRE) — Digirad Corporation (Nasdaq: DRAD) today reported its financial results for the third quarter and nine months ended September 30, 2018. Total revenues from continuing operations for the third quarter were $25.7 million, compared to $25.8 million in the third quarter of the prior […]
Esperion Provides Bempedoic Acid Franchise Development Program Updates; Reports Third Quarter 2018 Financial Results
ANN ARBOR, Mich., Nov. 01, 2018 (GLOBE NEWSWIRE) — Esperion (NASDAQ:ESPR), the Lipid Management Company focused on developing and commercializing complementary, convenient, cost-effective, once-daily, oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C), today provided bempedoic acid franchise development program updates and financial results for the third […]
Catasys Appoints Three Healthcare Executives to Board of Directors
LOS ANGELES–(BUSINESS WIRE)–Catasys, Inc. (NASDAQ:CATS) (“Catasys” or the “Company”), a leading AI and technology-enabled healthcare company, today announced the appointment of Edward Zecchini, Sharon Gabrielson, and Diane Seloff to its Board of Directors. Messrs. Rick Anderson and Dave Smith have stepped down as directors to accommodate the new Board members. […]
4TECH Inc. Reports First U.S. Clinical Implantations of Its TriCinch™ Coil Tricuspid Valve Repair System
GALWAY, Ireland–(BUSINESS WIRE)–4TECH Inc., a leader in the field of transcatheter tricuspid valve repair, initiated its U.S. Early Feasibility Study, following receipt of approval from the U.S. Food and Drug Administration (FDA), with the successful first two implantations of the TriCinch™ Coil System at Piedmont Heart Hospital, Atlanta, Georgia, by Dr. Christopher Meduri, Dr. Vivek […]
Cardiac Insight, Inc. Partners with VivoSense® (Vivonoetics, Inc.) to Expand the Use of Its Wearable Cardiac Sensors in Regulated Pharmaceutical Clinical Trials and Other Healthcare Research Applications
KIRKLAND, Wash.–(BUSINESS WIRE)–Cardiac Insight, Inc., a leading U.S. developer of wearable cardiac biosensors and clinical diagnostic software systems featuring proprietary automated data analysis algorithms, announced today it has partnered with VivoSense®, a leader in integration and specialized analysis of wearable sensor data for research and clinical trials. Together, both companies will […]
REVA Announces Commercial Launch of the Fantom Encore Bioresorbable Scaffold
SAN DIEGO, Oct. 31, 2018 (GLOBE NEWSWIRE) — REVA Medical, Inc. (ASX: RVA) (“REVA” or the “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the commercial launch of the Fantom Encore bioresorbable scaffold (“BRS”) and the first implant of Fantom Encore in the FANTOM Post Market Trial. […]
Abiomed Announces Q2 FY 2019 Record Revenue of $182 Million, up 37% Over Prior Year
DANVERS, Mass., Nov. 01, 2018 (GLOBE NEWSWIRE) — Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2019 revenue of $181.8 million, an increase of 37% compared to revenue of $132.8 million for the same period of fiscal 2018. Second quarter fiscal […]



